3 unknown, 2 recruiting, 2 terminated, 1 completed. 8 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Unknown 3, Recruiting 2, Terminated 2, Completed 1 |
| Phase 2 | 3 | Recruiting 2, Unknown 1 |
Follow Ovarian Clear Cell Carcinoma: new trials by email Literature Review of Ovarian Clear Cell Carcinoma trials Research Report on Ovarian Clear Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 Dostarlimab, LB-100 - Ovarian Clear Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 21 | 2023-11-10 | 2026-06-23 |
| Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma Zimberelimab, Metformin Hydrochloride - Ovarian Clear Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Fudan University | 20 | 2023-03-01 | 2023-03-08 |
| AMT-151 in Patients With Selected Advanced Solid Tumours AMT-151 - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Unknown | Multitude Therapeutics Inc. | 30 | 2023-01-25 | 2023-10-19 |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas APG-5918 - Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer | Phase 1 | Unknown | Ascentage Pharma Group Inc. | 90 | 2022-09-30 | 2022-11-16 |
| A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer NXP800 - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Terminated | Nuvectis Pharma, Inc. | 45 | 2021-12-31 | 2026-08-06 |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas Tulmimetostat, Enzalutamide - Advanced Solid Tumor, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 300 | 2019-09-18 | 2026-08-19 |
| A Study of PLX2853 in Advanced Malignancies. PLX2853 - Small Cell Lung Cancer, Uveal Melanoma | Phase 1 | Completed | Opna Bio LLC | 49 | 2017-09-12 | 2022-07-25 |
| A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma CDX-014 - Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma | Phase 1 | Terminated | Celldex Therapeutics | 16 | 2016-06-01 | 2020-06-04 |
Lymphoma, Non-Hodgkin (3) · Neoplasms (3) · Ovarian Neoplasms (3) · Carcinoma (2) · Endometrial Neoplasms (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Mesothelioma, Malignant (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Kidney Diseases (1)
Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Adenoma (3) · Adnexal Diseases (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Gonadal Disorders (3)
LB100 (1) · Metformin (1) · dostarlimab (1) · enzalutamide (1) · spartalizumab (1) · zimberelimab (1)
Ascentage Pharma Group Inc. (1) · Celldex Therapeutics (1) · Fudan University (1) · M.D. Anderson Cancer Center (1) · Multitude Therapeutics Inc. (1) · Novartis Pharmaceuticals (1) · Nuvectis Pharma, Inc. (1) · Opna Bio LLC (1)
United States (6) · United Kingdom (2) · Australia (1) · China (1) · France (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1)
Amir Jazaeri, M D (1) · Catherine Shannon (1) · Jermaine Coward (1) · Libing Xiang (1) · Mihitha Ariyapperuma (1) · Richardson Gary (1) · Sarwan Bishnoi (1) · Steven Kao (1) · Susana Banerjee, Dr (1) · Udai Banerji, Prof (1) · Yifan Zhai, MD, PhD (1)
2023 (1)